News
Germany’s Merck KGaA to acquire CT-based bioscience company in $3.9B deal
Two months after confirming “advanced talks” for a potential merger, Stamford-based SpringWorks Therapeutics Inc. on Monday announced a definitive agreement to be acquired by Germany-based Merck KGaA in a deal valued at about $3.
Merck KGaA, Darmstadt, Germany (DAX: MRK), a leading science and technology company, and SpringWorks Therapeutics, Inc.
Germany’s Merck KGaA has agreed to acquire U.S. biotech SpringWorks Therapeutics for $3.9 billion. The acquisition, aimed at ...
Merck KGaA said the deal will grow its U.S. presence and expand the reach of SpringWorks’ drugs, including one approved in February.
Merck KGaA, Darmstadt, Germany, a science and technology company, has entered into a definitive agreement to acquire ...
Germany's Merck KGaA will acquire US biotech firm SpringWorks Therapeutics for $3.9 billion. This strategic move aims to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback